Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

Berkeley Lights (Nasdaq: BLI), a life sciences tools company, and IsoPlexis (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million.

The combined company, which will be named PhenomeX (Nasdaq: CELL), will be a premier functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes. Under the terms of the agreement, which was unanimously approved by the Boards of Directors of both companies, IsoPlexis shareholders will receive 0.612 shares of Berkeley Lights stock for each IsoPlexis share they hold. Following the close of the transaction, Berkeley Lights shareholders will own approximately 75.2 percent of the combined company, and IsoPlexis shareholders will own approximately 24.8 percent of the combined company.

The combination of Berkeley Lights and IsoPlexis represents an important milestone and fuels our transformation into a growing, profitable, and sustainable life sciences company," said Siddhartha Kadia, Ph.D., chief executive officer of Berkeley Lights. "This transaction accelerates our progress across every core pillar of our strategic plan and creates a path to achieving positive operating cash flow earlier than we expected to as a standalone company. We look forward to joining forces with the IsoPlexis team as we embark on this next chapter and create value for our shareholders, employees, and customers."

Sean Mackay, co-founder and chief executive officer of IsoPlexis, said, "This transaction brings together two companies whose innovative solutions will help establish a technology leader in functional cell biology. The combined company will have a world-class team with complementary cultures and competencies to drive outcomes for customers and shareholders. We look forward to working together with the wonderful team at Berkeley Lights."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bruker Cellular Analysis. (2023, January 03). Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company. News-Medical. Retrieved on April 24, 2024 from https://www.news-medical.net/news/20230103/Berkeley-Lights-to-Acquire-IsoPlexis-Creating-a-Premier-Functional-Cell-Biology-Company.aspx.

  • MLA

    Bruker Cellular Analysis. "Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company". News-Medical. 24 April 2024. <https://www.news-medical.net/news/20230103/Berkeley-Lights-to-Acquire-IsoPlexis-Creating-a-Premier-Functional-Cell-Biology-Company.aspx>.

  • Chicago

    Bruker Cellular Analysis. "Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company". News-Medical. https://www.news-medical.net/news/20230103/Berkeley-Lights-to-Acquire-IsoPlexis-Creating-a-Premier-Functional-Cell-Biology-Company.aspx. (accessed April 24, 2024).

  • Harvard

    Bruker Cellular Analysis. 2023. Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company. News-Medical, viewed 24 April 2024, https://www.news-medical.net/news/20230103/Berkeley-Lights-to-Acquire-IsoPlexis-Creating-a-Premier-Functional-Cell-Biology-Company.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies